MariMed CCO converts RSUs, withholds shares for tax

Rhea-AI Filing Summary

MARIMED INC. Chief Commercial Officer Ryan Crandall reported RSU vesting and related tax withholding on July 15, 2026. He converted 32,813 Restricted Stock Units into common stock and had 11,370 shares withheld to cover taxes, leaving 1,124,246 common shares and 98,437 RSUs held directly. Remaining RSUs vest in three equal installments through April 15, 2027, and the transactions were not made under a Rule 10b5-1 plan.

Insider Trade Summary

32,813 shares exercised/converted

Exercise 3 txns

Insider Crandall Ryan

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units (RSU) F1, F3	32,813	$0.00	$0.00
Exercise	Common stock F1	32,813	$0.00	$0.00
Tax Withholding	Common stock F2	11,370	$0.0662	$752.69

Holdings After Transaction: Restricted Stock Units (RSU) — 98,437 contracts (Direct); Common stock — 1,124,246 shares (Direct)

Footnotes (3)

1. F1. RSUs convert to shares of common stock on a one-for-one basis.
2. F2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
3. F3. The RSUs were granted on April 15, 2026; the remaining RSUs under this grant will vest in three equal installments on each of October 15, 2026, January 15, 2027 and April 15, 2027, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

Key Figures

Shares acquired via RSU conversion: 32,813 shares Shares withheld for taxes: 11,370 shares Common shares held after transactions: 1,124,246 shares +3 more

6 metrics

Shares acquired via RSU conversion 32,813 shares Restricted Stock Units converting into common stock on 2026-07-15

Shares withheld for taxes 11,370 shares Common shares withheld to satisfy tax withholding obligations on RSU vesting

Common shares held after transactions 1,124,246 shares Direct common stock ownership after the tax-withholding disposition

RSUs remaining after conversion 98,437 units Restricted Stock Units outstanding following the 32,813-unit conversion

Tax withholding price per share 0.0662 per share Per-share value used for the 11,370-share tax-withholding disposition

Future RSU vesting dates October 15, 2026; January 15, 2027; April 15, 2027 Scheduled vesting dates for remaining RSUs from the April 15, 2026 grant

Key Terms

Restricted Stock Units (RSU), tax withholding obligations, Rule 10b5-1 plan

3 terms

Restricted Stock Units (RSU) financial

"The security title is listed as Restricted Stock Units (RSU)."

tax withholding obligations financial

"shares of common stock withheld by the Issuer to satisfy tax withholding obligations"

Rule 10b5-1 plan financial

"The transactions were not made under a Rule 10b5-1 plan."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MariMed (MRMD) report for Ryan Crandall?

MariMed disclosed that Chief Commercial Officer Ryan Crandall vested 32,813 RSUs on July 15, 2026, which converted into common stock. In connection with this vesting, a portion of the resulting shares was withheld to satisfy tax obligations rather than sold on the open market.

How many MariMed (MRMD) shares were withheld for Ryan Crandall’s taxes and why?

The company withheld 11,370 common shares from Ryan Crandall to satisfy tax withholding obligations tied to his RSU vesting. This is reported as a disposition coded “F,” reflecting payment of tax liability by delivering securities back to the issuer instead of paying cash.

After the July 15, 2026 transactions, how many MariMed (MRMD) shares and RSUs does Ryan Crandall hold?

Following the reported transactions, Ryan Crandall directly held 1,124,246 shares of MariMed common stock and 98,437 Restricted Stock Units. These figures reflect the RSU conversion into shares plus the share withholding for taxes as detailed in the Form 4 filing.

What is the future vesting schedule for Ryan Crandall’s remaining MariMed (MRMD) RSUs?

The remaining RSUs from the April 15, 2026 grant vest in three equal installments on October 15, 2026, January 15, 2027 and April 15, 2027. Each vesting date will convert one-third of the outstanding RSUs into MariMed common stock under the award agreement.

Were Ryan Crandall’s MariMed (MRMD) transactions made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox was not selected, meaning these transactions were not reported as being executed under a pre-arranged trading plan. They are instead presented as standard equity compensation and related tax withholding events.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 04:12 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crandall Ryan

(Last) (First) (Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD MASSACHUSETTS 02062

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	07/15/2026		M		32,813	A	$0(1)	1,135,616	D
Common stock	07/15/2026		F		11,370(2)	D	$0.0662	1,124,246	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSU)	(1)	07/15/2026		M			32,813	(3)	(3)	Common Stock, par value $.001 per share	32,813	$0	98,437	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.

3. The RSUs were granted on April 15, 2026; the remaining RSUs under this grant will vest in three equal installments on each of October 15, 2026, January 15, 2027 and April 15, 2027, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

Remarks:

	/s/ Ryan Crandall	07/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)